| Host: |
Rabbit |
| Applications: |
WB |
| Reactivity: |
Human |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Rabbit polyclonal antibody anti-SPRY3 (C-Term) is suitable for use in Western Blot research applications. |
| Clonality: |
Polyclonal |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
PBS with 0.01% Thimerosal, 50% Glycerol, pH7.3. |
| Purification: |
Affinity purification |
| Dilution Range: |
WB 1:500-1:2000 |
| Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Gene Symbol: |
SPRY3 |
| Gene ID: |
10251 |
| Uniprot ID: |
SPY3_HUMAN |
| Immunogen Region: |
C-Term |
| Immunogen: |
A synthetic peptide corresponding to a sequence within amino acids 200 to the C-terminus of human SPRY3 (NP_005831.1). |
| Immunogen Sequence: |
TDDEDNCADEPCSCGPSSCF VRWAAMSLISLFLPCLCCYL PTRGCLHLCQQGYDSLRRPG CRCKRHTNTVCRKISSGSAP FPKAQEKSV |
| Tissue Specificity | Widely expressed.particularly in the fetal tissues. Expressed in the brain with expression the highest in Purkinje cells in the cerebellum (at protein level). Expressed in the myocardium of the heart. |
| Function | Inhibits neurite branching, arbor length and neurite complexity. Inhibits EGF-mediated p42/44 ERK signaling. Negatively regulates the MAPK cascade, resulting in a reduction of extracellular matrix protein accumulation. May function as an antagonist of fibroblast growth factor (FGF) pathways and may negatively modulate respiratory organogenesis. |
| Protein Name | Protein Sprouty Homolog 3Spry-3Sprouty Rtk Signaling Antagonist 3Sprouty3 |
| Cellular Localisation | Cytoplasm |
| Alternative Antibody Names | Anti-Protein Sprouty Homolog 3 antibodyAnti-Spry-3 antibodyAnti-Sprouty Rtk Signaling Antagonist 3 antibodyAnti-Sprouty3 antibodyAnti-SPRY3 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
